Breaking News Instant updates and real-time market news.

TSRO

TESARO

$99.26

-0.63 (-0.63%)

14:39
10/09/16
10/09
14:39
10/09/16
14:39

TESARO reports Phase 3 data on niraparib in ovarian cancer, says met endpoint

TESARO announced the presentation of the niraparib Phase 3 ENGOT-OV16/NOVA clinical trial results at the ESMO 2016 Congress. ENGOT-OV16/NOVA is a Phase 3 trial of niraparib that enrolled 553 patients with recurrent ovarian cancer who were in response to their most recent platinum-based chemotherapy. The trial successfully achieved its primary endpoint in both cohorts, demonstrating that niraparib treatment significantly prolonged PFS compared to control in patients who were germline BRCA mutation carriers and in patients who were not germline BRCA mutation carriers. In addition, within the non-gBRCA cohort, niraparib treatment significantly prolonged PFS compared to control for the prospectively defined patient population with tumors deficient in homologous recombination. Specifically, among patients who were germline BRCA mutation carriers, the niraparib arm successfully achieved statistical significance over the control arm for the primary endpoint of PFS, with a hazard ratio of 0.27. The median PFS for patients treated with niraparib was 21.0 months, compared to 5.5 months for control. Niraparib also showed statistical significance for patients in the non-germline BRCA mutant cohort. The niraparib arm successfully achieved statistical significance over the control arm for the primary endpoint of PFS, with a hazard ratio of 0.45. The median PFS for patients treated with niraparib was 9.3 months, compared to 3.9 months for control. For patients who were not germline BRCA mutation carriers but whose tumors were determined to be HRD positive, the niraparib arm successfully achieved statistical significance over the control arm for the primary endpoint of PFS, with a hazard ratio of 0.38. The median PFS for patients with HRD-positive tumors who were treated with niraparib was 12.9 months, compared to 3.8 months for control. Secondary endpoint analyses, including chemotherapy-free interval, time to first subsequent treatment, and PFS 2 were all statistically significant and favored niraparib over control for patients in both the gBRCAmut and non-gBRCAmut cohorts. Patient-reported outcome results from validated survey tools indicated that niraparib-treated patients reported no difference from control in measures associated with quality of life. Data for overall survival are immature, as fewer than 20% of events had occurred at the time of analysis. The most common treatment-emergent grade 3/4 adverse events in the niraparib arm were thrombocytopenia in 33.8%, anemia in 25.3%, and neutropenia in 19.6%. The majority of these hematological laboratory abnormalities occurred within the first three cycles; following dose modifications the incidence of these lab abnormalities decreased and thrombocytopenia and neutropenia were infrequent beyond cycle 3. There were no deaths among patients during study treatment. A high proportion of patients in both treatment groups in both cohorts had received three or more prior lines of chemotherapy.

  • 06

    Nov

  • 11

    Jan

TSRO TESARO
$99.26

-0.63 (-0.63%)

09/21/16
09/21/16
NO CHANGE

RBC identifies top biotech takeover candidates
RBC Capital identified the following names as its top potential takeover candidates in the biotech space: ARIAD (ARIA), Spark Therapeutics (ONCE), BioMarin (BMRN), Aerie Pharmaceuticals (AERI), Intra-Cellular (ITCI), TESARO (TSRO), Incyte (INCY), Sarepta (SRPT), and Puma Biotechnology (PBYI). The firm thinks that investors are underestimating the positive impact that M&A will have on biotech stock prices.
09/21/16
LEER
09/21/16
NO CHANGE
LEER
Outperform
PARP addition makes sense for Eli Lilly oncology, says Leerink
In the wake of recent speculation that Eli Lilly (LLY) has expressed interest in acquiring Clovis (CLVS), Leerink analyst Seamus Fernandez says the addition of a PARP inhibitor makes strategic sense, fitting in "extremely well" with the former's oncology portfolio. Further, the analyst believes that the "impressive" emerging data from the PARP inhibitor class is likely to place both TESARO (TSRO) and Clovis high on the list of potential M&A targets. Fernandez reiterates an Outperform rating on Eli Lilly's shares.
09/26/16
BOFA
09/26/16
NO CHANGE
Target $109
BOFA
Buy
TESARO price target raised to $109 from $95 at BofA/Merrill
BofA/Merrill analyst Doug Leggate raised Teseor's price target to $109 from $95 following management meetings that suggest current EBITDA is about $800M, ahead of management targets. Shares are Buy rated.
10/07/16
PIPR
10/07/16
NO CHANGE
PIPR
Neutral
Piper still sees Clovis' rucaparib getting broader indication than Lynparza
Piper Jaffray analyst Steven Breazzano said the rucaparib response rates in platinum resistant and platinum refractory patients of 25% and 0%, respectively, reported by Clovis Oncology (CLVS) are lower than some may have been expecting and "seemingly negative on the surface." However, he continues to believe rucaparib will be approved in BRCA patients who have received 2+ lines of therapy, which is an earlier and broader patient population than assigned to competitor AstraZeneca's (AZN) Lynparza, he tells investors. The ultimate market potential and key to success is the maintenance setting, for which TESARO's (TSRO) niraparib is still best-positioned, adds Breazzano, who keeps a Neutral rating on Clovis shares.

TODAY'S FREE FLY STORIES

DISCA

Discovery

$29.62

0.94 (3.28%)

05:38
02/22/17
02/22
05:38
02/22/17
05:38
Downgrade
Discovery rating change  »

Discovery downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ISIL

Intersil

$22.20

0.02 (0.09%)

, RNECY

Renesas

05:38
02/22/17
02/22
05:38
02/22/17
05:38
Hot Stocks
Intersil, Renesas announce regulatory approval for acquisition of Intersil »

Renesas Electronics…

ISIL

Intersil

$22.20

0.02 (0.09%)

RNECY

Renesas

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ENTL

Entellus Medical

$17.08

0.06 (0.35%)

05:36
02/22/17
02/22
05:36
02/22/17
05:36
Downgrade
Entellus Medical rating change  »

Entellus Medical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MNTA

Momenta

$16.05

-2.95 (-15.53%)

05:34
02/22/17
02/22
05:34
02/22/17
05:34
Downgrade
Momenta rating change  »

Leerink downgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BG

Bunge

$78.44

0.66 (0.85%)

05:33
02/22/17
02/22
05:33
02/22/17
05:33
Hot Stocks
Bunge forms JV with Bahri, terms not disclosed »

Bahri Dry Bulk, or BDB, a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

AU

AngloGold

$12.54

-0.36 (-2.79%)

05:30
02/22/17
02/22
05:30
02/22/17
05:30
Downgrade
AngloGold rating change  »

AngloGold downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TOL

Toll Brothers

$31.99

0.5 (1.59%)

05:27
02/22/17
02/22
05:27
02/22/17
05:27
Hot Stocks
Toll Brothers backs FY17 adjusted gross margin »

Toll Brothers reaffirms…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

STM

STMicroelectronics

$14.64

0.38 (2.66%)

05:27
02/22/17
02/22
05:27
02/22/17
05:27
Upgrade
STMicroelectronics rating change  »

STMicroelectronics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AZSEY

Allianz

$17.45

0.13 (0.75%)

05:25
02/22/17
02/22
05:25
02/22/17
05:25
Initiation
Allianz initiated  »

Allianz initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IHG

InterContinental

$48.62

0.42 (0.87%)

05:25
02/22/17
02/22
05:25
02/22/17
05:25
Downgrade
InterContinental rating change  »

InterContinental…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LUKOY

Lukoil

$55.80

0.87 (1.58%)

05:24
02/22/17
02/22
05:24
02/22/17
05:24
Upgrade
Lukoil rating change  »

Lukoil upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TOL

Toll Brothers

$31.99

0.5 (1.59%)

05:23
02/22/17
02/22
05:23
02/22/17
05:23
Earnings
Toll Brothers reports Q1 EPS 42c, consensus 35c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

QCOM

Qualcomm

$56.75

0.29 (0.51%)

, CHL

China Mobile

$56.46

0.35 (0.62%)

05:17
02/22/17
02/22
05:17
02/22/17
05:17
Hot Stocks
Qualcomm, China Mobile, ZTE announce collaboration on 5G NR trials »

Qualcomm Technologies, a…

QCOM

Qualcomm

$56.75

0.29 (0.51%)

CHL

China Mobile

$56.46

0.35 (0.62%)

ZTCOY

ZTE Corp.

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Mar

ECL

Ecolab

$124.03

0.08 (0.06%)

04:58
02/22/17
02/22
04:58
02/22/17
04:58
Downgrade
Ecolab rating change  »

Ecolab downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GIS

General Mills

$61.02

1.79 (3.02%)

, TSN

Tyson Foods

$63.31

-1.95 (-2.99%)

04:55
02/22/17
02/22
04:55
02/22/17
04:55
Conference/Events
The Consumer Analyst Group of New York to hold a conference »

2017 CAGNY Conference is…

GIS

General Mills

$61.02

1.79 (3.02%)

TSN

Tyson Foods

$63.31

-1.95 (-2.99%)

TWNK

Hostess Brands

$15.47

-0.13 (-0.83%)

MJN

Mead Johnson

$87.47

-0.03 (-0.03%)

K

Kellogg

$74.74

1.84 (2.52%)

MDLZ

Mondelez

$44.97

2.47 (5.81%)

INGR

Ingredion

$122.02

1.23 (1.02%)

LNCE

Snyder's-Lance

$39.38

0.38 (0.97%)

SYY

Sysco

$52.81

0.46 (0.88%)

JNJ

Johnson & Johnson

$119.66

0.8 (0.67%)

SJM

J.M. Smucker

$141.92

5.97 (4.39%)

MO

Altria Group

$73.65

0.68 (0.93%)

CPB

Campbell Soup

$58.95

0.47 (0.80%)

PEP

PepsiCo

$109.36

1.21 (1.12%)

CLX

Clorox

$135.44

1.73 (1.29%)

BG

Bunge

$78.44

0.66 (0.85%)

PG

Procter & Gamble

$91.67

0.58 (0.64%)

DANOY

Danone

$12.92

-0.125 (-0.96%)

SPB

Spectrum Brands

$134.58

0.67 (0.50%)

KO

Coca-Cola

$41.46

0.23 (0.56%)

IFF

International Flavors

$121.62

-0.75 (-0.61%)

STZ

Constellation Brands

$160.09

-1.23 (-0.76%)

NSRGY

Nestle

$72.92

-0.825 (-1.12%)

CHD

Church & Dwight

$49.61

-0.09 (-0.18%)

UN

Unilever; also tag UL

$45.09

-3.7 (-7.58%)

CL

Colgate-Palmolive

$73.18

1.2 (1.67%)

NWL

Newell Brands

$46.49

-0.15 (-0.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 24

    Feb

  • 09

    Mar

  • 14

    Mar

  • 15

    Mar

  • 19

    Mar

  • 27

    Mar

  • 09

    May

RIO

Rio Tinto

$44.89

0.65 (1.47%)

04:55
02/22/17
02/22
04:55
02/22/17
04:55
Conference/Events
Rio Tinto management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 23

    Feb

  • 24

    Feb

  • 26

    Feb

CRUS

Cirrus Logic

$55.17

-0.16 (-0.29%)

04:55
02/22/17
02/22
04:55
02/22/17
04:55
Conference/Events
Cirrus Logic management to meet with Canaccord »

Meetings to be held on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

VWDRY

Vestas

$24.97

0.34 (1.38%)

04:55
02/22/17
02/22
04:55
02/22/17
04:55
Conference/Events
Vestas management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 23

    Feb

MPWR

Monolithic Power

$88.22

1.7 (1.96%)

04:55
02/22/17
02/22
04:55
02/22/17
04:55
Conference/Events
Monolithic Power management to meet with Oppenheimer »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 23

    Feb

  • 04

    Apr

  • 05

    Apr

WEB

Web.com

$20.40

0.2 (0.99%)

04:55
02/22/17
02/22
04:55
02/22/17
04:55
Conference/Events
Web.com management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 23

    Feb

OCLR

Oclaro

$10.97

-0.05 (-0.45%)

04:55
02/22/17
02/22
04:55
02/22/17
04:55
Conference/Events
Oclaro management to meet with MKM Partners »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 03

    Mar

HAS

Hasbro

$98.88

0.38 (0.39%)

04:55
02/22/17
02/22
04:55
02/22/17
04:55
Conference/Events
Hasbro management to meet with MKM Partners »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 22

    Feb

FLWS

1-800-Flowers.com

$10.10

0.1 (1.00%)

04:55
02/22/17
02/22
04:55
02/22/17
04:55
Conference/Events
1-800-Flowers.com management to meet with Benchmark »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 23

    Feb

04:55
02/22/17
02/22
04:55
02/22/17
04:55
General news
Breaking General news story  »

FOMC Minutes to be…

04:55
02/22/17
02/22
04:55
02/22/17
04:55
General news
Breaking General news story  »

Federal Reserve Gov.…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.